Showing 71-80 of 3069 results for "".
Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyJoel Schlessinger MD Discusses Personal Phones in the Office
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-discusses-personal-phones-in-the-office-/19276/Dealing with personal phone use at work is an issue that almost every business must consider. While it is important that people are available in case of an emergency, this rule can often be abused. In this video, Joel Schlessinger MD offers his advice on dealing with this office issue. Dr. Joel SEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iScientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReThe Biggest Developments in Dermatology: Drs. Tsao and Friedlander Provide Updates at Maui Derm
https://practicaldermatology.com/issues/january-february-2025/the-biggest-developments-in-dermatology-drs-tsao-and-friedlander-provide-updates-at-maui-derm/32937/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, adopted a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.A Broad View of the Current Literature
https://practicaldermatology.com/conferences/maui-derm-2024/a-broad-view-of-the-current-literature/20263/Resident Of Distinction Award-winner Jason Klein, MD, PhD, a dermatology resident at the UT Southwestern Medical Center, talks about some of the latest developments in dermatology literature highlighted in review presentations at Maui Derm 2024, including an elegant synopsis of current options for tAdvances in Wound Care
https://practicaldermatology.com/conferences/maui-derm-2022/maui-derm-2022-video/20040/Robert S. Kirsner, MD, PhD discusses the latest in wound healing science and resulting changes in how leading wound care experts are approaching patient care. From innovative products to greater understanding of the science, there are many options to help patients heal.SARS-CoV-2 and the Skin: Inside the COVID-19 Dermatology Registry
https://practicaldermatology.com/conferences/aad-2021/sars-cov-2-and-the-skin-inside-the-covid-19-dermatology-registry/19921/From COVID Toes to COVID Arms, dermatologic manifestations of SARS-CoV-2 infection and COVID-19 vaccination abound. Esther Freeman, MD, PhD, Director of the COVID-19 Dermatology Registry provides an overview of findings and shares information about the relatively new vaccine registry.Improving Patient Outcomes
https://practicaldermatology.com/topics/practice-management/improving-patient-outcomes/19102/Steven Feldman, MD, PhD, Professor of Dermatology at Wake Forest University in Winston-Salem, NC, discusses typical patterns of how patients use their medications and identifies strategies for improving adherence and building trust with patients. DermTube's coverage of the AAD's 2014 Summer MeetingAnti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.